Biogen Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Biogen Inc Company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Biogen Inc Info



Ticker SymbolBIIB

Company nameBiogen Inc

IPO dateSep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

Number of employees7605

Security typeOrdinary Share

Fiscal year-endSep 17

Address225 Binney Street

CityCAMBRIDGE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02142

Phone17814642000

Websitehttps://www.biogen.com/

Ticker SymbolBIIB

IPO dateSep 17, 1991

CEOMr. Christopher A. (Chris) Viehbacher

Company Executives of Biogen Inc



Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-8.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

Name

Name/Position

Position

Shareholding

Change

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

Other

498.00M

18.82%

By RegionUSD

Name

Revenue

Proportion

United States

1.38B

52.21%

Rest of World

937.60M

35.44%

United states-Revenues from anti-CD20 therapeutic

467.30M

17.66%

Rest of World-Other revenues

244.60M

9.25%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

Other

498.00M

18.82%

Shareholding Stats

Updated: Tue, Aug 19

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

Other

63.53%

Shareholders

Proportion

The Vanguard Group, Inc.

11.74%

PRIMECAP Management Company

10.78%

BlackRock Institutional Trust Company, N.A.

5.59%

State Street Global Advisors (US)

5.09%

Wellington Management Company, LLP

3.27%

Other

63.53%

Shareholder Types

Shareholders

Proportion

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

24.28%

Hedge Fund

8.68%

Pension Fund

2.62%

Research Firm

2.27%

Sovereign Wealth Fund

1.59%

Bank and Trust

1.38%

Individual Investor

0.17%

Venture Capital

0.14%

Other

7.32%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1987

135.68M

92.54%

-8.70M

2025Q2

2075

135.74M

92.58%

-12.69M

2025Q1

2149

136.82M

93.38%

-11.44M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

17.21M

11.74%

+255.44K

+1.51%

Jun 30, 2025

PRIMECAP Management Company

15.80M

10.78%

-141.14K

-0.89%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.19M

5.59%

-504.36K

-5.80%

Jun 30, 2025

State Street Global Advisors (US)

7.47M

5.09%

+71.90K

+0.97%

Jun 30, 2025

Wellington Management Company, LLP

4.80M

3.27%

+125.98K

+2.70%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.92M

2.67%

+71.29K

+1.85%

Jun 30, 2025

Point72 Asset Management, L.P.

3.83M

2.61%

+3.42M

+840.86%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

3.00M

2.05%

-10.62K

-0.35%

Aug 31, 2025

Norges Bank Investment Management (NBIM)

2.26M

1.54%

-61.02K

-2.62%

Jun 30, 2025

Invesco Capital Management LLC

2.04M

1.39%

+32.06K

+1.59%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

iShares Neuroscience and Healthcare ETF

3.81%

First Trust NASDAQ Pharmaceuticals ETF

3.54%

VanEck Biotech ETF

3.36%

First Trust NYSE Arca Biotechnology Index Fund

3.19%

Invesco Pharmaceuticals ETF

2.45%

SPDR S&P Biotech ETF

2.31%

First Trust Health Care Alphadex Fund

2.26%

Invesco Nasdaq Biotechnology ETF

1.98%

ProShares Ultra Nasdaq Biotechnology

1.97%

iShares Health Innovation Active ETF

1.96%

iShares Neuroscience and Healthcare ETF

Proportion3.81%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.54%

VanEck Biotech ETF

Proportion3.36%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.19%

Invesco Pharmaceuticals ETF

Proportion2.45%

SPDR S&P Biotech ETF

Proportion2.31%

First Trust Health Care Alphadex Fund

Proportion2.26%

Invesco Nasdaq Biotechnology ETF

Proportion1.98%

ProShares Ultra Nasdaq Biotechnology

Proportion1.97%

iShares Health Innovation Active ETF

Proportion1.96%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data